A&G Pharmaceutical: Fighting Cancer.avi

>> PHARMA OR BIOTECH TAKES A LONG TIME, IT’S LIKE A GOOD WINE. IT TAKES A LONG TIME TO MATURE, AND YOU KNOW, AND COME TO FULL REALIZATION, AND THIS IS ACTUALLY ONE OF THE CHALLENGES ABOUT IN [indistinct] SITUATION, TO BE ABLE TO SUPPORT EFFORTS THAT TAKE YEARS AND YEARS TO COME TO A PRODUCT. >> SHE BROUGHT IN THE GP88 TECHNOLOGY WHICH IS THE CANCER THERAPY AND DIAGNOSTIC, AND I BROUGHT IN THE RAPID ANTIBODY DEVELOPMENT TECHNOLOGY. WHAT WE DO IS THAT WE MAKE MONOCLONAL ANTIBODIES IN RECORD TIME. AND SO, WE REALLY PROVIDE THE TOOLS TO RESEARCHERS AND PHARMACEUTICAL COMPANIES, THE TOOLS TO DIG FOR GOLD. THE PHARMACEUTICAL COMPANIES, PRESUMABLY THEY KNOW WHERE THE GOLD IS. SO THAT’S WHAT WE DO. AND THEN OF COURSE, WE HAVE OUR OWN GOLD MINE, WHICH IS THE GP88. >> SO WE HAVE TWO DIAGNOSTIC PRODUCTS, THE TISSUE TEST, THE BLOOD TEST, AND THE THERAPEUTIC PRODUCT DEVELOPMENT. WE WERE ABLE TO SHOW, WE COMPLETED A BIG STUDY TO SHOW THAT WHEN THIS PROTEIN IS EXPRESSED INTO CANCER, IT PREDICTS, IT WILL TELL THE PATIENT THAT IT WILL RECUR FASTER. SO WHEN THIS PROTEIN IS VERY HIGH IN THE CANCER OF THIS PATIENT, THIS PATIENT WILL HAVE A FOUR-FOLD HIGHER CHANCE TO RECUR WITHIN FIVE YEARS, AND THAT’S VERY IMPORTANT FROM THE ONCOLOGISTS TO KNOW, IT’S CALLED THE STRATIFICATION OF THE PATIENT. THEY NEED TO KNOW WHO IS DOING POORLY BECAUSE THEN THEY WILL TREAT THEM MORE AGRESSIVELY. BUT YOU CAN’T TELL A PATIENT YOU HAVE A HIGHER RISK OF YOUR DISEASE RECURRING, THIS IS LIKE HAVING A SWORD OVER YOUR HEAD IF YOU DON’T KNOW WHEN YOU’RE GOING TO RECOVER. OUR BLOOD TESTS WILL ALLOW TO MONITOR THE PATIENTS AND SEE HOW WELL THEY’RE DOING, RESPONDING TO THERAPY, OR HOW WELL THEIR DISEASE IS PROGRESSING. AND RIGHT NOW, WE’VE JUST FINISHED THIS STUDY, WE ARE NEGOTIATING TO COMMERCIALIZE OUR DIAGNOSTIC PRODUCTS, SO IT’S TRULY, YOU KNOW, THE FIRST PART OF THE DREAM COMING TRUE.

Leave a Reply

(*) Required, Your email will not be published